What's Going On With REGENXBIO Shares Monday?

REGENXBIO Inc. (NASDAQ:RGNX) stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy.

The Details: The company announced that it has dosed the first patient in its trial for RGX-202, a potential gene therapy designed to treat Duchenne muscular dystrophy.

In addition, REGENXBIO announced positive results from the Phase I/II portion of the study. Specifically, the company saw functional improvements in all patients treated with dose level one and dose level two at 12 and 9 months respectively. A favorable safety profile was observed at both dose levels, with no serious adverse events.

“The totality of our ...

Full story available on Benzinga.com